Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc EVP Marshall Urist reported an open-market sale of 9,098 Class A Ordinary Shares of RPRX at a weighted average price of $55.1843 per share. After this transaction, he directly holds 9,099 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026, meaning the trades were scheduled in advance rather than timed discretionarily.
Royalty Pharma plc executive Christopher Hite reported pre-planned insider sales linked to an affiliated entity. On June 23, 2026, SCH Investment Partners LLC, an entity associated with Hite, sold a total of 150,000 Class A Ordinary Shares in open-market transactions at weighted average prices of $54.47 and $54.11 per share.
All transactions were executed under a Rule 10b5-1 trading plan adopted on March 20, 2026, indicating they were scheduled in advance. Following these sales, SCH Investment Partners LLC held 676,991 Class A Ordinary Shares indirectly for Hite, while he also held 70,000 shares directly.
Royalty Pharma plc (RPRX) reported reported Form 144 activity showing insider transactions by Marshall Urist. The filing lists sales of 13,684 shares on 05/14/2026 for $726,137.82 and 13,684 shares on 05/20/2026 for $721,837.21. The excerpt also shows a 9,098-share Equity Performance Award granted on 05/08/2026.
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini filed Amendment No. 8 to their Schedule 13D on Royalty Pharma plc, updating their ownership and corporate details. As of June 12, 2026, they may be deemed to beneficially own 21,366,927 Class A shares, representing 4.8% of the outstanding class based on 443,274,104 shares. The amendment notes that they are no longer deemed beneficial owners of more than five percent of Royalty Pharma’s Class A shares and states this is their final amendment and exit filing. The filing also records the trust and fund structure through which the shares are held and disclaims beneficial ownership by various board members and beneficiaries.
Royalty Pharma plc director Elizabeth H. Weatherman received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units. The grant was made at no cash cost to her and is classified as a compensation-related acquisition, not an open-market purchase.
The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to the company’s 2020 Independent Director Equity Incentive Plan and the award agreement. After this grant, she holds 13,103 shares directly.
Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Gregory Norden received a new equity grant. On June 5, 2026, he was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units at a price of $0.00 per share under the company’s 2020 Independent Director Equity Incentive Plan.
The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholders’ meeting, subject to plan and award terms. Following this grant, Norden directly holds 196,348 Class A Ordinary Shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares on a grant basis, with no cash paid per share. The award is in the form of restricted stock units under the company’s 2020 Independent Director Equity Incentive Plan. These units are generally scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the date of the next annual shareholder meeting, subject to plan and award terms. Following this grant, Love directly holds 58,393 Class A Ordinary Shares.
Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation. The award was granted under the company’s 2020 Independent Director Equity Incentive Plan and is scheduled to vest 100% on the earlier of one year from grant or the next annual shareholder meeting. The restricted stock units are held solely for the benefit of General Atlantic Service Company, L.P., and Hodgson disclaims beneficial ownership of the underlying shares. Following this grant, 37,873 Class A ordinary shares are reported as directly held.